RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - Phase 1/2 Data Ultragenyx Pharmaceutical Inc. announced positive Phase 1/2 data for GTX-102, an investigational treatment for Angelman syndrome, showing significant cognitive improvements in patients, with a mean change in cognition score of +10.9 and 80% of patients achieving meaningful improvement.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC